Novavax’s Updated COVID Vaccine Candidate Neutralizes Emerging Subvariants

Novavax’s vaccine candidate against new sublineages of COVID-19 is showing promising results in small animal and non-human primate studies. The company announced Tuesday that its XBB COVID vaccine candidate induced neutralizing antibody responses in the EG.5.1 and XBB.1.16.6 subvariants, dubbed Eris and Fornax, respectively.